Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib vs Irinotecan in Docetaxel-Pretreated NSCLC
NCT00319800Phase 2Unknown
- Sponsor
- Gachon University Gil Medical Center
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Gachon University Gil Medical Center. Primary endpoints: Objective Response Rate and Progression-Free Survival. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00319800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319800.